TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30300371

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention (medication adjustment, stepped mental health care, exercise therapy)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Multifactorial intervention
Number of subjects: 168

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 168
Study: 28665259

Group type: EXPERIMENTAL
Intervention: Lenvatinib (24 mg/day; 28-day cycle)
Number of subjects: 392

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: Lenvatinib
Number of subjects: 392
Study: 26610844

Group type: COMPARATOR
Intervention: Tafenoquine regimen with three daily loading doses plus weekly maintenance at 200‐mg for 10 weeks or longer
Number of subjects: 492

Group type: COMPARATOR
Intervention: Tafenoquine 200‐mg weekly
Number of subjects: 492

Group type: COMPARATOR
Intervention: Mefloquine 250‐mg weekly
Number of subjects: 492

Group type: COMPARATOR
Intervention: Tafenoquine with a three‐day loading dose at 400‐mg
Number of subjects: 492

Group type: COMPARATOR
Intervention: Tafenoquine with a three‐day loading dose at 400‐mg without follow-up weekly maintenance doses
Number of subjects: 492
Study: 24282608

Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI) before 5 years of age
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI) after 5 years of age
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Cochlear Implant (CI) with more than 5 years of implant use
Number of subjects: 42

Group type: COMPARATOR
Intervention: Cochlear Implant (CI) regardless of age at implantation
Number of subjects: 42
Study: 20499075

Group type: EXPERIMENTAL
Intervention: Early clamping (<10 s post-delivery)
Number of subjects: 158

Group type: COMPARATOR
Intervention: Delayed clamping (2 min post-delivery)
Number of subjects: 158
Study: 18343056

Group type: EXPERIMENTAL
Intervention: Testosterone supplementation in combination with hormone replacement therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional postmenopausal hormone therapy
Number of subjects: 0
Study: 17348310

Group type: EXPERIMENTAL
Intervention: Foley's catheter alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Extra-amniotic instillation of Prostaglandin F-2 alpha (PGF2 alpha) via Foley's catheter
Number of subjects: 60
Study: 14561238

Group type: EXPERIMENTAL
Intervention: Flunarizine
Number of subjects: 20
Study: 10971167

Group type: EXPERIMENTAL
Intervention: Cisplatin (20 mg/m(2)), Ifosfamide (1.5 g/m(2)), Irinotecan (60 mg/m(2)) with rhG-CSF support
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Cisplatin (15 mg/m(2)), Irinotecan (50 mg/m(2)) with rhG-CSF support (after dose adjustment)
Number of subjects: 18
Study: 8840939

Group type: EXPERIMENTAL
Intervention: Isotonic bicarbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isotonic saline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Insulin + bicarbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Insulin + saline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Albuterol + bicarbonate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Albuterol + saline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bicarbonate administration
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline administration
Number of subjects: 0
Study: 1473671

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (no intravenous sedative)
Number of subjects: 84
Study: 6387112

Group type: EXPERIMENTAL
Intervention: Standard intrauterine devices (IUDs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified intrauterine devices for postpartum use
Number of subjects: 0

Group type: COMPARATOR
Intervention: Interval insertions of IUDs
Number of subjects: 0
Study: 30764631

Group type: EXPERIMENTAL
Intervention: p16 positive tumors
Number of subjects: 49

Group type: COMPARATOR
Intervention: p16 negative tumors
Number of subjects: 49
Study: 30391274

Group type: EXPERIMENTAL
Intervention: Low-intensity with blood flow restriction 'High' (LI + BFR_H)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Low-intensity with blood flow restriction 'Low' (LI + BFR_L)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: High-intensity (HI)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Low-intensity (LI)
Number of subjects: 56
Study: 26490710

Group type: EXPERIMENTAL
Intervention: Psychoeducation on complicated grief and helpful social support
Number of subjects: 0

Group type: COMPARATOR
Intervention: Psychoeducation on complicated grief
Number of subjects: 0
Study: 25305728

Group type: EXPERIMENTAL
Intervention: MACS (magnetic activated cell sorting) with swim-up preparation
Number of subjects: 237

Group type: COMPARATOR
Intervention: Control group (swim-up preparation)
Number of subjects: 237
Study: 21616737

Group type: EXPERIMENTAL
Intervention: Culturally appropriate, low-cost lifestyle intervention for diabetes prevention
Number of subjects: 0
Study: 19854483

Group type: EXPERIMENTAL
Intervention: 5% tramadol (2 mg/kg) plus adrenaline (0.0125/mL)
Number of subjects: 40

Group type: COMPARATOR
Intervention: 2% prilocaine plus adrenaline (0.0125/mL)
Number of subjects: 40
Study: 18076231

Group type: EXPERIMENTAL
Intervention: 80% 1RM squat
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 80% 1RM deadlift
Number of subjects: 16

Group type: COMPARATOR
Intervention: Body weight squat, deadlift, superman, sidebridge
Number of subjects: 16
Study: 15882280

Group type: EXPERIMENTAL
Intervention: Regional citrate anticoagulation
Number of subjects: 30

Group type: COMPARATOR
Intervention: Systemic heparin anticoagulation
Number of subjects: 30
Study: 12359778

Group type: EXPERIMENTAL
Intervention: CAIV-T (first dose)
Number of subjects: 1314

Group type: EXPERIMENTAL
Intervention: CAIV-T (second dose)
Number of subjects: 1314

Group type: EXPERIMENTAL
Intervention: CAIV-T (year 2)
Number of subjects: 1314

Group type: EXPERIMENTAL
Intervention: CAIV-T (years 3 and 4)
Number of subjects: 1314

Group type: EXPERIMENTAL
Intervention: CAIV-T (between days 11 and 42)
Number of subjects: 1314

Group type: EXPERIMENTAL
Intervention: CAIV-T (years 1 to 4)
Number of subjects: 1314

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1314
Study: 10426648

Group type: EXPERIMENTAL
Intervention: Indoramin 20 mg orally twice a day
Number of subjects: 49

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study: 7760573

Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Mirror exposure with alcohol
Number of subjects: 47

Group type: COMPARATOR
Intervention: Mirror exposure with placebo
Number of subjects: 47
Study: 1969208

Group type: EXPERIMENTAL
Intervention: Ketoconazole shampoo, twice weekly for 4 weeks
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 7286046

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg) evening ingestion
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg) morning ingestion
Number of subjects: 9
Study: 30653305

Group type: EXPERIMENTAL
Intervention: Sand barrier latrines
Number of subjects: 68

Group type: COMPARATOR
Intervention: Latrines without sand barriers
Number of subjects: 68
Study: 27604762

Group type: EXPERIMENTAL
Intervention: Indocyanine green (ICG)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Brilliant blue G (BBG)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Triamcinolone acetonide (TA)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 48
Study: 25885962

Group type: EXPERIMENTAL
Intervention: Patient information website (www.orthoanswer.org)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard discussion with the treating surgeon (Control)
Number of subjects: 0
Study: 24099315

Group type: EXPERIMENTAL
Intervention: Self-management program
Number of subjects: 132

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 132
Study: 21285719

Group type: EXPERIMENTAL
Intervention: Shockwave lithotripsy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Medical expulsive therapy with alpha-blockers
Number of subjects: 0
Study: 18953506

Group type: EXPERIMENTAL
Intervention: Adjuvant sodium selenite 0.2 mg kg(‐1) day(‐1) for 7 days in addition to chemotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard chemotherapy
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Adjuvant sodium selenite
Number of subjects: 40
Study: 17907391

Group type: COMPARATOR
Intervention: Manual Acupuncture (MA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Electroacupuncture (EA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 14982568

Group type: EXPERIMENTAL
Intervention: Intrathecal 10 mg of hyperbaric tetracaine with 0.2 mg of epinephrine (SE Group)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Intrathecal 10 mg of hyperbaric tetracaine (L Group)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Intrathecal 10 mg of hyperbaric tetracaine (S Group)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Atropine for bradycardia
Number of subjects: 96
Study: 11172138

Group type: EXPERIMENTAL
Intervention: Discontinuation of primary prophylaxis
Number of subjects: 587

Group type: EXPERIMENTAL
Intervention: Discontinuation of secondary prophylaxis
Number of subjects: 587
Study: 9458381

Group type: EXPERIMENTAL
Intervention: 5-HT3-Receptor Antagonist (5-HT3-RA)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Low-dose oral metoclopramide (20 mg q.i.d.) + i.m. Dexamethasone (M + D)
Number of subjects: 51
Study: 7931196

Group type: EXPERIMENTAL
Intervention: Model tasks with unique hiding places
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model tasks with identical hiding places
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model tasks with aligned models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model tasks with non-aligned models
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Model tasks for 5-year-olds
Number of subjects: 0
Study: 2455099

Group type: EXPERIMENTAL
Intervention: Cyproterone acetate (CPA), 100 mg p.o./day plus tamoxifen (TAM), 100 mg p.o./day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flutamide (FLU), 750 mg p.o./day
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CPA plus TAM treated patients
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FLU treated patients
Number of subjects: 0
Study: 31855018

Group type: EXPERIMENTAL
Intervention: Therapeutic Couples Intervention (TCI)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 75
Study: 29703119

Group type: EXPERIMENTAL
Intervention: Brief Admission (BA)
Number of subjects: 8
Study: 27982182

Group type: EXPERIMENTAL
Intervention: 0.5% sodium hypochlorite
Number of subjects: 32

Group type: COMPARATOR
Intervention: water (control)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: alkaline peroxide
Number of subjects: 32
Study: 24434659

Group type: EXPERIMENTAL
Intervention: bimatoprost 0.01%
Number of subjects: 60
Study: 22538142

Group type: EXPERIMENTAL
Intervention: 5-bevel pen needle (PN)
Number of subjects: 30
Study: 21275333

Group type: EXPERIMENTAL
Intervention: Music therapy (15-35 minute session with live patient-preferred music and therapeutic social interaction)
Number of subjects: 58
Study: 18162859

Group type: EXPERIMENTAL
Intervention: QI-Therapy
Number of subjects: 1300
Study: 17560638

Group type: EXPERIMENTAL
Intervention: Traditional Chinese herbal remedies
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional drugs (corticosteroids)
Number of subjects: 0
Study: 14680665

Group type: EXPERIMENTAL
Intervention: Participation in a randomized controlled trial
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Reasons for nonparticipation
Number of subjects: 667
Study: 11152170

Group type: EXPERIMENTAL
Intervention: CRM-induced skin responses and serum-specific IgE responses
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: CRM-induced skin responses
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Serum-specific IgE levels
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Serum-specific IgG4 levels
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Serum-specific IgG1 levels
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation of skin responses to CRM with serum-specific IgE levels
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation of serum CRM-specific IgE levels with specific IgG1 and IgG4 levels
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Correlation between serum IgG1 and IgG4 levels
Number of subjects: 100
Study: 9177986

Group type: EXPERIMENTAL
Intervention: Formula supplemented with omega‐3 and omega‐6 long‐chain polyunsaturated fatty acids and cholesterol (n = 12)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional formula (n = 10)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 22
Study: 8478475

Group type: EXPERIMENTAL
Intervention: Argon laser treatment for mature nodular port-wine stains, telangiectasia, small vascular lesions, and superficial pigmented lesions.
Number of subjects: 0
Study: 3928674

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2) at 50 micrograms/24 h and higher
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2) at 25, 50, 100, and 200 micrograms/24 h
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transdermal estradiol (E2)
Number of subjects: 0
Study: 29388413

Group type: EXPERIMENTAL
Intervention: Water swallowing
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Saliva swallowing
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both swallowing tasks
Number of subjects: 16
Study: 29927201

Group type: EXPERIMENTAL
Intervention: High dose proton pump inhibitor (PPI) - intravenous pantoprazole 80 mg bolus then continuously drip 8 mg per hour
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard dose proton pump inhibitor (PPI) - intravenous pantoprazole 40 mg twice daily
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: High dose proton pump inhibitor (PPI)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Standard dose proton pump inhibitor (PPI)
Number of subjects: 113
Study: 24118885

Group type: EXPERIMENTAL
Intervention: AZD7687 (1, 2.5, 5, 10 and 20 mg/day)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: AZD7687 (doses >5 mg/day)
Number of subjects: 62
Study: 22090395

Group type: EXPERIMENTAL
Intervention: MK-0929
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 20409605

Group type: EXPERIMENTAL
Intervention: Artificial Neural Network (ANN)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Logistic models
Number of subjects: 250
Study: 18331385

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP)
Number of subjects: 1868

Group type: EXPERIMENTAL
Intervention: C-reactive protein thresholds (40, 60, 120 mg/l)
Number of subjects: 1868

Group type: EXPERIMENTAL
Intervention: Combination of raised CRP concentration with clinical diagnosis of pneumonia
Number of subjects: 1868
Study: 15944791

Group type: EXPERIMENTAL
Intervention: Platinum-based combination chemotherapy (CTX)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No chemotherapy (no-CTX)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: First-line chemotherapy (CTX)
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Second-line chemotherapy (CTX)
Number of subjects: 63
Study: 12582393

Group type: EXPERIMENTAL
Intervention: Topical methyl aminolevulinate (MAL) 160 mg/g
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 80
Study: 10226473

Group type: EXPERIMENTAL
Intervention: 35% oxygen during exercise
Number of subjects: 10

Group type: COMPARATOR
Intervention: Room air during exercise
Number of subjects: 10
Study: 10684406

Group type: EXPERIMENTAL
Intervention: Lovastatin 20 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluvastatin 20 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 0
Study: 1984374

Group type: EXPERIMENTAL
Intervention: In vivo phosphorus nuclear magnetic resonance (31P NMR) spectroscopy
Number of subjects: 42

Group type: COMPARATOR
Intervention: In vitro halothane/caffeine contracture test
Number of subjects: 42
Study: 6404404

Group type: EXPERIMENTAL
Intervention: Home environment
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hospital environment
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Home environment during activity
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hospital environment during activity
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Home environment (sphygmomanometry)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hospital environment (sphygmomanometry)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Home environment (diastolic pressure)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Hospital environment (diastolic pressure)
Number of subjects: 9
Study: 30596964

Group type: EXPERIMENTAL
Intervention: Oral amoxicillin suspension (50 mg/kg/day) for 3 days
Number of subjects: 15749

Group type: COMPARATOR
Intervention: Oral co-trimoxazole suspension (8 mg trimethoprim/kg and 40 mg sulfamethoxazole/kg/day) for 5 days
Number of subjects: 15749
Study: 29344840

Group type: EXPERIMENTAL
Intervention: Ticagrelor 90 mg twice daily
Number of subjects: 120

Group type: COMPARATOR
Intervention: Clopidogrel 75 mg once daily
Number of subjects: 120
Study: 27813031

Group type: EXPERIMENTAL
Intervention: IV dexketoprofen trometamol (50 mg)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IV acetaminophen (1 gr)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No analgesic (Control Group K)
Number of subjects: 60
Study: 24008791

Group type: EXPERIMENTAL
Intervention: Capsular tension ring (CTR)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control (only IOL)
Number of subjects: 34
Study: 22617396

Group type: EXPERIMENTAL
Intervention: BOLUS (25 g of whey protein + 5 g of leucine dissolved in artificially sweetened water; 1 × 500 mL)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: PULSE (15 × 33‐mL aliquots of BOLUS drink every 15 min)
Number of subjects: 12

Group type: COMPARATOR
Intervention: PLAC (artificially sweetened water)
Number of subjects: 12
Study: 20033128

Group type: EXPERIMENTAL
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Transurethral microwave therapy (TUMT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Laser-assisted techniques
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bipolar resection
Number of subjects: 0
Study: 17276321

Group type: EXPERIMENTAL
Intervention: Motivational interviewing training for dietitians
Number of subjects: 209

Group type: COMPARATOR
Intervention: Control dietitians (no training)
Number of subjects: 209
Study: 15690909

Group type: EXPERIMENTAL
Intervention: Gepon 0.04% ointment
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Immunomax 200 units intramuscularly, administered 3 times every 2nd day
Number of subjects: 126

Group type: COMPARATOR
Intervention: Routine surgical treatment and drug therapy (control group)
Number of subjects: 126
Study: 12577246

Group type: EXPERIMENTAL
Intervention: Intravenous amifostine (200 mg/m2/d in a short 3‐minute infusion 15 to 30 minutes before each fraction of radiotherapy)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Subcutaneous amifostine (500 mg/d in two, slow 1.25‐mL injections at two different sites 20 to 60 minutes before each radiotherapy fraction)
Number of subjects: 54
Study: 9660331

Group type: EXPERIMENTAL
Intervention: Polylactic acid bioabsorbable barrier
Number of subjects: 10

Group type: COMPARATOR
Intervention: ePTFE non-resorbable barrier
Number of subjects: 10
Study: 7806089

Group type: COMPARATOR
Intervention: Erythropoietin (Epo) evaluation in endurance runners
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) evaluation during a 6-hour race
Number of subjects: 46
Study: 2590272

Group type: EXPERIMENTAL
Intervention: Two-layered polyurethane foam wound dressing (Lyomousse)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (no treatment specified)
Number of subjects: 41
Study: 30732181

Group type: EXPERIMENTAL
Intervention: Photobiomodulation using red and infrared LEDs (660 nm and 850 nm) with a power of 3.5 mW per LED, 6 sessions over 2 weeks.
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo group (details not specified).
Number of subjects: 33

Group type: COMPARATOR
Intervention: Control group (details not specified).
Number of subjects: 33
Study: 28743343

Group type: EXPERIMENTAL
Intervention: HD + HF + HP group (HD for 8 times a month + HF for 4 times a month + HP once a month)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: HD + HF group (HD for 8 times a month + HF once a month)
Number of subjects: 120

Group type: COMPARATOR
Intervention: HD group (HD for 8 times a month)
Number of subjects: 120
Study: 25567758

Group type: EXPERIMENTAL
Intervention: Nurse-led behavioral management intervention (tailored DM and HTN content)
Number of subjects: 377

Group type: COMPARATOR
Intervention: Control group (non-tailored, non-interactive information)
Number of subjects: 377
Study: 23505124

Group type: EXPERIMENTAL
Intervention: Aripiprazole 9.75 mg IM injection
Number of subjects: 201
Study: 21682350

Group type: EXPERIMENTAL
Intervention: DRV/r monotherapy (800/100 mg once daily)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Triple therapy (two NRTIs + DRV/r)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: DRV/r monotherapy
Number of subjects: 256

Group type: COMPARATOR
Intervention: Triple therapy
Number of subjects: 256
Study: 19623782

Group type: EXPERIMENTAL
Intervention: Transfer factor
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 15900378

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) 40 mg/kg/day in 5% dextrose
Number of subjects: 26

Group type: COMPARATOR
Intervention: 5% dextrose (placebo)
Number of subjects: 26
Study: 10480768

Group type: EXPERIMENTAL
Intervention: Asymptomatic hyperglycemia
Number of subjects: 8006

Group type: EXPERIMENTAL
Intervention: Known diabetes
Number of subjects: 8006

Group type: EXPERIMENTAL
Intervention: High-normal glucose tolerance
Number of subjects: 8006

Group type: COMPARATOR
Intervention: Low-normal glucose tolerance
Number of subjects: 8006